Clinical Trials Browser

Recruiting × Prostatic Diseases × Clear all

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05413850 2026-03-02

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Phase 1/2 Recruiting

82 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06785636 2025-11-14

P300

Phase 1/2 Recruiting

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07130708 2025-08-19

Exploring the Potential of Robotic Telesurgery in Remote Settings

Phase NA Recruiting

10 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT05574647 2025-07-24

IP7-PACIFIC

Phase NA Recruiting

3,600 enrolled

Genitourinary

Adenocarcinoma, Neoplasms, Prostatic Diseases, Prostatic Neoplasms

NCT04597411 2025-03-21

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Phase 1 Recruiting

99 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06190899 2025-03-21

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase 3 Recruiting

500 enrolled

Genitourinary

Genital Diseases, Male, Prostatic Diseases

NCT06706921 2024-11-27

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Phase 4 Recruiting

15 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06636747 2024-10-15

High Resolution Diffusion Weighted Imaging in Prostate

Recruiting

500 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms

Clinical Trials

STRIKE-001

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

P300

Exploring the Potential of Robotic Telesurgery in Remote Settings

IP7-PACIFIC

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

High Resolution Diffusion Weighted Imaging in Prostate